A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Allograft Recipients

Interventions

BIOLOGICAL: Belatacept
DRUG: Tacrolimus
DRUG: Cyclosporine A
DRUG: Mycophenolate Mofetil
DRUG: Enteric Coated Mycophenolate Sodium
DRUG: Corticosteroids

Sponsor

Bristol-Myers Squibb